Endotoxin as a drug target

Critical Care Medicine

Volumn 31, Issue 1 SUPPL., 2003, Pages

  Opal, Steven M ^a   Glück, Thomas ^b  

^a BROWN UNIVERSITY   (United States)

^b Department of Internal Medicine   (United States)

Author keywords

Antiendotoxin antibodies; Cytokines; Endotoxin; Sepsis; Septic shock

Indexed keywords

CYTOKINE; ENDOTOXIN; ENDOTOXIN ANTIBODY;

BACTERIAL MEMBRANE; BLOOD CLOTTING; CIRCULATION; ENDOTOXEMIA; GRAM NEGATIVE BACTERIUM; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MORTALITY; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; SURVIVAL; VACCINATION;

EID: 0037247571     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-200301001-00009     Document Type: Review

References (79)

1. Cross AS, Opal SM: Therapeutic intervention in sepsis with antibody to endotoxin: Is there a future? J Endotoxin Res 1994; 1:57-69
2. Pridmore AC, Wyllie DH, Abdillahi F, et al: A lipopolysaccharide-deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via toll-like receptor (TLR) 2 but not via TLR4/MD2. J Infect Dis 2001; 183:89-96
3. Rietschel ET, Kirikae T, Schade FU, et al: Bacterial endotoxin: Molecular mechanisms of structure to activity and function. FASEB J 1994; 218:217-225
4. Opal SM: The phylogenetic relationships between the coagulation system and the inflammatory networks. Crit Care Med 2000; 28:S77-S82
5. Opal SM, Yu RL Jr: Antiendotoxin strategies for the prevention and treatment of septic shock new approaches and future directions. Drugs 1998; 55:497-508
6. Van Deventer SJM, Bullet HR, ten Cate JW, et al: Endotoxemia as an early predictor of septicaemia in febrile patients. Lancet 1988; I:605-608
7. Danner RL, Elin RJ, Hosseini JM, et al: Endotoxemia in human septic shock. Chest 1991; 99:169-175
8. Opal SM, Scannon PJ, Vincent JL, et al: Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis 1999; 180:1584-1589
9. Huang Q, Liu D, Majewski P, et al: The plasticity of dendritic cell responses to pathogens and their components. Science 2001; 294:870-875
10. Medzhitov R, Janeway C: Innate immunity. N Engl J Med 2000; 343:338-344
11. Fenton MJ, Golenbock DT: LPS-binding proteins and receptors. J Leukoc Biol 1998; 64:25-32
12. Antal-Szalmas P: Evaluation of CD14 in host defense. Eur J Clin Invest 2000; 30:167-179
13. Landmann R, Müller B, Zimmerli W: CD14, new aspects of ligand and signal diversity. Microb Infect 2000; 2:295-304
14. Pugin J, Heumann ID, Tomasz A, et al: CD14 is a pattern recognition receptor. Immunity 1994; 1:509-516
15. Poltorak A, He X, Smirnova I, et al: Defective signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 1998; 282:2085-2088
16. Pfeiffer A, Böttcher A, Orsó E, et al: Lipopolysaccharide and ceramide docking to CD14 provokes ligand specific receptor clustering in rafts. Eur J Immunol 2001; 31:3153-3164
17. Opal SM, Huber C. The toll-like receptors and their role in septic shock. Critical Care 2002; 6:125-136
18. Means TK, Golenbock DT, Fenton MJ: The biology of toll-like receptors. Cytokine Growth Factor Rev 2000; 11:219-232
19. Burgmann H, Winkler S, Locker GJ, et al: Increased serum concentration of soluble CD14 is a prognostic marker in Gram-positive sepsis. Clin Immunol Immunopathol 1996; 80:307-310
20. Krüger C, Schütt C, Obertacke U, et al: Serum CD14 levels in polytraumatized and severely burned patients. Clin Exp Immunol 1991; 85:297-301
21. Landmann R, Zimmerli W, Sansano S, et al: Increased circulating soluble CD14 is associated with high mortality in Gram-negative septic shock. J Infect Dis 1995; 171:639-644
22. Haziot A, Rong GW, Lin XY, et al: Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol 1995; 154:6529-6532
23. Kollef MH, Shermann G, Ward S, et al: Inadequate antimicrobial treatment of infections. A risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-474
24. Dofferhoff ASM, Buys J: The influence of antibiotic-induced filament formation on the release of endotoxin from Gram-negative bacteria. J Endotoxin Res 1996; 3:187-194
25. Jackson JJ, Kropp H: Differences in mode of action of β-lactam antibiotics influence morphology, LPS-release and in vivo antibiotic efficacy. J Endotoxin Res 1996; 3:201-218
26. Simpson AJ, Opal SM, Prins J, et al: Antibiotic-induced endotoxin release in the treatment of acute septicemic melioidosis. J Infect Dis 2000; 181:1014-1019
27. Ziegler EJ, McCutchan JA, Fierer J, et al: Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307:1225-1230
28. Girardin E, and the J5 Study Group: Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: A prospective double-blind study. J Infect Dis 1992; 165:695-701
29. Calandra T, Glauser MP, Schellekens J, et al: Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coli J5: A prospective, double-blind, randomized trial. J Infect Dis 1988; 158:312-318
30. Cornetta A, Baumgartner JD, Lee ML, et al: Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 1992; 327:234-240
31. Ziegler EJ, Fisher CJ, Sprung CL, et al: Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991; 324:429-436
32. Greenman RL, Schein RMH, Martin MA, et al: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. JAMA 1991; 266:1097-1102
33. McCloskey RV, Straube RC, Sanders C, et al: Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, placebo-controlled trial. CHESS trial study group. Ann Intern Med 1994; 121:1-5
34. French National Registry of HA-1A: The French national registry of HA-1A (Centoxin) in septic shock. A cohort-study of 600 patients. The national committee for the evaluation of Centoxin. Arch Intern Med 1994; 154:2484-2491
35. Bone RC, Balk RA, Fein AM, et al: A second large controlled clinical study of E5, a monoclonal antibody to endotoxin. Results of a prospective, multicenter, randomized, controlled trial. The E5 sepsis study group. Crit Care Med 1995; 23:994-1006
36. Angus DC, Birmingham MC, Balk RA, et al: E5 murine monoclonal antiendotoxin antibody in Gram-negative sepsis: A randomized controlled trial. E5 Study Investigators. JAMA 2000; 283:1723-1730
37. Daifuku R, Haenftling K, Young J, et al: Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88. Antimicrob Agents Chemother 1992; 10:2349-2351
38. Baumgartner JD: Immunotherapy with antibodies to core lipopolysaccharide: A critical appraisal. Infect Dis Clin North Am 1991; 5:915-927
39. Marra MN, Thornton MB, Snable JL, et al: Endotoxin binding and neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5. Crit Care Med 1994; 22:559-565
40. Warren HS, Amato SF, Fitting C, et al: Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med 1993; 177:89-97
41. Bennett-Guerrero E, Ayuso L, Hamilton-Davies H, et al: Relationship of preoperative antiendotoxin core antibodies and adverse outcomes following cardiac surgery. JAMA 1997; 277:646-650
42. Goldie AS, Fearon KCH, Ross JA, et al: Natural cytokine and endogenous antiendotoxin core antibodies in sepsis syndrome. JAMA 1995; 274:172-177
43. Nys M, Damas P, Joassin L, et al: Sequential anti-core glycolipid immunoglobulin antibody activities with and without septic shock and their relation to outcome. Ann Surg 1993; 217:300-306
44. Bhattacharjee AK, Opal SM, Taylor R, et al: A non-covalent complex vaccine prepared with detoxified E. coli J5 LPS and Neisseria meningitidis group B outer membrane protein produces protective antibodies against Gram-negative bacteria. J Infect Dis 1996; 173:1157-1162
45. Cross AS, Opal SM, Warren SH, et al: Active immunization with a detoxified Escherichia coli J5 lipopolysaccharide group B meningococcal outer membrane protein complex vaccine protects animals from experimental sepsis. J Infect Dis 2001; 183:1079-1086
46. Vuorio R, Vaara M: The lipid A biosynthesis mutation of lpxA2 of Escherichia coli results in drastic antibiotic supersusceptibility. Antimicrob Agents Chemother 1992; 36:826-829
47. Onishi HR, Pelak BA, Gerskens LS, et al: Antibacterial agents that inhibit lipid A biosynthesis. Science 1996; 274:980-982
48. Hammond SM, Claesson A, Jansson AM, et al: A new class of synthetic antibacterials acting on lipopolysaccharide biosynthesis. Nature 1987; 327:730-732
49. Wurfel MM, Kunitake ST, Lichtenstein H, et al: Lipopolysaccharide binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994; 180:1025-1035
50. Wurfel M, Hailman E, Wright SD: Soluble CD14 acts as a shuttle in the neutralization of lipopolysaccharide (LPS) by LPS binding protein and reconstituted high density lipoprotein. J Exp Med 1995; 181:1743-1754
51. Kitchens RL, Thompson PA, Viriyakosol S, et al: Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest 2001; 108:485-493
52. Lamping N, Dettmer R, Schröder NWJ, et al: LPS-binding protein protects mice from septic shock caused by LPS or Gram-negative bacteria. J Clin Invest 1998; 101:2065-2071
53. Haziot A, Ferrero E, Kontgen F, et al: Resistance to endotoxin shock and reduced dissemination of Gram-negative bacteria in CD14-deficient mice. Immunity 1996; 4:407-414
54. Haziot A, Hijiya N, Schultz K, et al: CD14 plays no major role in shock induced by Staphylococcus aureus but down-regulates TNF-α-production. J Immunol 1999; 162:4801-4805
55. Leturcq DJ, Moriarty AM, Talbott G, et al: Antibodies against CD14 protect primates from endotoxin-induced shock. J Clin Invest 1996; 98:1533-1538
56. Frevert CW, Matute-Bello G, Skerrett SJ, et al: Effect of CD14 blockade in rabbits with Escherichia coli pneumonia and sepsis. J Immunol 2000; 164:5439-5455
57. Verbon A, Dekkers PEP, ten Hove T, et al: IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 2001; 166:3599-3605
58. Reinhart K, Glueck T, Ligtenberg J, et al: Phase 1 study with recombinant chimeric monoclonal antibody against human CD14 (IC14) in patients with severe sepsis. Crit Care Med 2001; 29(Suppl):A19
59. Stelter F, Witt S, Furll B, et al: Different efficacy of soluble CD14 treatment in high-and low-dose LPS models. Eur J Clin Invest 1998; 28:205-213
60. Elsbach P, Weiss J. Bactericidal/permeability-increasing protein and host defense against Gram-negative bacteria in endotoxin. Curr Opin Immunol 1993; 5:103-107
61. Marra MN, Wilde CG, Griffith JE, et al: Bactericidal/permeability-increasing protein has endotoxin-neutralizing ability. J Immunol 1990; 144:662-666
62. Bermer LJ, Carroll SF, Eisenberg D: Crystal structure of human BPI and two bound phospholipids at 4.5 angstrom resolution. Science 1997; 276:1861-1864
63. 21) as adjunctive treatment for children with severe meningococcal sepsis: A randomised trial. Lancet 2000; 356:961-967
64. Levels JHM, Abraham PR, van den Ende A, et al: Distribution and kinetics of lipoprotein-bound endotoxin. Infect Immun 2001; 69:2821-2828
65. Rauchaus M, Coats AJS, Anker SD: The endotoxin-lipoprotein hypothesis. Lancet 2000; 356:930-933
66. Harris HW, Johnson JA, Wigmore SJ: Endogenous lipoproteins impact the response to endotoxin in humans. Crit Care Med 2002; 30:23-31
67. Gordon BR, Parker TS, Levine DM, et al: Low lipid concentrations in critical illness: Implications for preventing and treating endotoxemia. Crit Care Med 1996; 24:584-589
68. Levine DM, Parker TS, Donnelly TM, et al: In-vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A 1993; 90:12040-12044
69. Pajkrt D, Doran JE, Coster F, et al: Anti-inflammatory affects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184:1601-1608
70. Opal SM: Hemofiltration-absorption systems for the treatment of experimental sepsis: Is it possible to remove the "evil humors" responsible for septic shock? Crit Care Med 2000; 28:1681-1682
71. Rogiers P, Zhang H, Nagler J, et al: Hemofiltration in sepsis and septic shock: Where do we stand? Intensivmed 1998; 35:228-234
72. Tani T, Hanasawa K, Endo Y, et al: Therapeutic apheresis for septic patients with organ-dysfunction: Hemoperfusion using a polymixin B immobilized column. Artif Organs 1998; 22:1038-1045
73. Ullrich H, Jakob W, Fröhlich D, et al: A new endotoxin absorber: First clinical application. Ther Apher 2001; 5:326-334
74. Christ WJ, Osamu A, Robidoux ALC, et al: E5531 a pure endotoxin antagonist of high potency. Science 1995; 268:80-83
75. Kawata T, Bristol JR, Rose JR, et al: Anti-endotoxin activity of a novel synthetic lipid A analog. Prog Clin Biol Res 1995; 392:499-509
76. Hawkins LD, Ishizaka ST, McGuiness P, et al: A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4 dependent immunostimulatory action, and adjuvant activity. J Pharmacol Exp Ther 2002; 300:655-666
77. Bunell E, Lynn M, Habet K, et al: A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia. Crit Care Med 2000; 28:2713-2720
78. Cohen J: TREM-1 in sepsis. Lancet 2001; 358:776-778
79. Savransky JE, Schaked G, Novogrodsky A, et al: Tyrphostin AG556 improves survival and reduces multi-organ failure in canine Escherichia coli peritonitis. J Clin Invest 1997; 99:1966-1973